4th Quarter - Report

MARSHALL & POPP, LLC for JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to the research and development of cannabis-derived therapies, the regulatory framework for CBD, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R. 2617, Consolidated Appropriations Act.

LobbyistCovered position, as disclosed
HAZEN CLAY MARSHALL Policy Director-Senate Majority Leader Mitch McConnell; Staff Director/Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles
MONICA POPP Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6833 (117th), S. 4348 (117th), H.R. 2617 (117th)

Banking BAN

Issues related to the definition of business of insurance, including: S.910/H.R.1996: The SAFE Banking Act. S.862: CLAIM Act.

LobbyistCovered position, as disclosed
HAZEN CLAY MARSHALL —
MONICA POPP —

Contacted: SENATE

Bills named: S. 862 (117th), H.R. 1996 (117th), S. 910 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.